Scientists from the United Kingdom may have identified several more environmental causes for cancer after evaluating the genetic data of over 12,000 cancer patients from National Health Service files.
ReutersHealth authorities around the world are investigating a mysterious increase in severe cases of hepatitis – inflammation of the liver – in young children.
AbbVie terminated the company’s collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.
Although research is being conducted on Long COVID or Long COVID-19, whose symptoms continue for weeks and months after initial infection, there are very few ongoing clinical trials on treatments. Anecdotally, there has been what appears to be a successful treatment for Long Covid using Pfizer’s antiviral regimen Paxlovid.
Mallinckrodt plc announced the publication of findings from a retrospective chart review study assessing the real-world use and outcomes of INOmax (nitric oxide) gas, for inhalation therapy in hospitalized patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome (ARDS), a disorder in which fluid leaks into the lungs, making breathing difficult or impossible. The results of the study were published in the peer-reviewed journal Drugs in Context.
Ansa Biotechnologies, a California-based start-up focused on updating DNA synthesis technologies, is advancing toward the launch of a customizable DNA synthesis service, stemming from the development of a novel synthesis method.
Published April 07, 2022 By Alex Keown BioSpace Jazz Pharmaceuticals continues to advance its efforts toward becoming a leading oncology company via a key licensing deal with Werewolf Therapeutics for […]
Although people who recover from COVID-19 usually gain some immune defenses against reinfection, they get additional protection from vaccines, especially against severe disease, according to two studies published on March 31 in The Lancet Infectious Diseases. Additionally, two gold-standard trials published in The New England Journal of Medicine on March 30 help settle questions about two controversial therapies touted by many early in the pandemic with decidedly mixed results – failure for the antiparasite drug ivermectin and success for antibody-rich blood plasma from COVID-19 survivors.
Scientists on March 31 published the first complete human genome, filling in gaps remaining after previous efforts while offering new promise in the search for clues regarding disease-causing mutations and genetic variation among the world’s 7.9 billion people.
Anosmia is a recognized symptom of COVID-19, with anywhere between 30% to 80% of sufferers reporting loss of smell.
